InvestorsHub Logo
Followers 468
Posts 26929
Boards Moderated 2
Alias Born 09/11/2006

Re: None

Wednesday, 01/02/2008 8:42:54 AM

Wednesday, January 02, 2008 8:42:54 AM

Post# of 69
Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
Monday December 31, 8:30 am ET

CARLSBAD, Calif., Dec. 31 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA - News) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 2a clinical trial evaluating RDEA806, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), in patients with human immunodeficiency virus (HIV), the causative agent of AIDS.
http://biz.yahoo.com/prnews/071231/aqm005.html?.v=33


surf's up......crikey